Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer-Reference-Cited by-同舟云学术

Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer

Published:2024-03-16 Issue:1 Volume:42 Page:
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Nikitas John,Kishan Amar,Chang Albert,Duriseti Sai,Nichols Nicholas G.,Reiter Robert,Rettig Matthew,Brisbane Wayne,Steinberg Michael L.,Valle Luca^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00345-024-04862-0.pdf

Reference37 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/CAAC.21708

2. Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990–2007. World J Urol 26(3):211–218. https://doi.org/10.1007/S00345-008-0250-7

3. Nezolosky M, Nguyen PL, Yang DD (2018) Which patients with localized prostate cancer account for the greatest proportion of prostate cancer deaths? JCO 36(6_suppl):130 https://doi.org/10.1200/JCO.2018.36.6_SUPPL.130

4. Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N (2014) Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses. Clin Oncol (R Coll Radiol) 26(10):e21–e46. https://doi.org/10.1016/J.CLON.2014.06.016

5. Kishan AU, Sun Y, Hartman H et al (2022) Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol 23(2):304–316. https://doi.org/10.1016/S1470-2045(21)00705-1